argenx SE (NASDAQ:ARGX) Shares Purchased by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC increased its position in shares of argenx SE (NASDAQ:ARGX) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 380 shares of the company’s stock after purchasing an additional 20 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in argenx were worth $234,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC raised its position in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC raised its position in argenx by 0.4% during the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after acquiring an additional 10,975 shares in the last quarter. Wellington Management Group LLP raised its position in argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after acquiring an additional 55,617 shares in the last quarter. Alkeon Capital Management LLC raised its position in argenx by 15.0% during the third quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after acquiring an additional 45,000 shares in the last quarter. Finally, Jennison Associates LLC raised its position in argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after acquiring an additional 64,183 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the subject of several recent research reports. Evercore ISI lifted their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. HC Wainwright upped their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Robert W. Baird upped their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 4th. Guggenheim upped their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Stock Performance

Shares of ARGX stock opened at $604.96 on Friday. The stock has a fifty day moving average price of $638.53 and a 200 day moving average price of $595.17. The stock has a market cap of $36.76 billion, a PE ratio of -687.45 and a beta of 0.59. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. As a group, equities research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.